Comparative study of pulmonary functions and oxidative stress in smokers and non-smokers

Indian Journal of Physiology and Pharmacology

Volumn 56, Issue 4, 2012, Pages 345-352

  Waseem, Shah Mohammad Abbas ^a   Hossain, Mohd Mobarak ^a   Islam, Najmul ^a   Ahmad, Zuber ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Catalase; Gender; GPX (Glutathione Peroxidase); MDA (Malondialdehyde); Smoking; SOD (Superoxide Dismutase)

Indexed keywords

CATALASE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUPEROXIDE DISMUTASE;

ADULT; AGE; ANTIOXIDANT ACTIVITY; ARTICLE; BODY MASS; BODY WEIGHT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SMOKING;

ADULT; FEMALE; HUMANS; LUNG; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING;

EID: 84871007825     PISSN: 00195499     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. WHO site http://www.who.int world bank/WHO global burden of disease study.
2. Jindal SK. Emergence of Chronic Obstructive Pulmonary Disease as an Epidemic in India. Indian J Med Res 2006; 124: 619-630.
3. Jindal SK. Indian Multicentric Study on Epidemiology of Asthma and Chronic Bronchitis in Adults (INSEARCH) Study, ICMR Report 2010.
4. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2008.
5. Buist AS, Vollmer VM, McBurnie MA. Worldwide burden of COPD in high and low income countries. Part I: The burden of obstructive lung disease (BOLD). Initiative Int J Tuber C Lung Dis 2008; 12: 703-708.
6. Rahman I, MacNee W. Role of oxiadnts/antioxidants in smoking induced lung diseases. Free Rad Biol Med 1996; 21: 669-681.
7. MacNee W, Donaldson K. Environmental factors in COPD. London: B.C. Decker 2002; 145-160.
8. Lundback B, Lindberg A, Lindstrom M, Rönmark E, Jonsson AC, Jönsson E, Larsson LG, Andersson S, Sandström T, Larsson K. Not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003; 97: 115-122.
9. Saetta M, Turato G, Maestrelli P, et al. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1304-1309.
10. Sherrill DL, Lebowitz MD, Burrows B. Epidemiology of chronic obstructive pulmonary disease. Clin Chest Med 1990; 11: 375-387.
11. Lange P, Groth S, Nyboe J et al. Effects of smoking and changes in smoking habits on the decline of FEV1. Eur Respir J 1989; 2: 811-816.
12. National Family Health Survey (NFHS-3) India;Vol 1, Table 13.10, Page 433(2005-2006).MOHFW/GOI
13. Gupta A, Prakash C. Indian Journal of Medical Research 2006; 14: 254-257.
14. Cabrera NP, Perez PR. COPD: an ambiguous name and an obstacle in the campaign against smoking. Arch Bronconeumol 2004; 40: 480-482.
15. de Migucl DJ. In support of the term chronic obstructive pulmonary disease (COPD). Arch Bronconeumol 2004; 40: 480-482.
16. Brandt CJ, Ellegaard H, Joensen MB, Sorknaes D et al. The diagnosis of smokers lung encourages smoking cessation. Lancet 1997; 349: 253.
17. Aebi HE. Catalase in vitro. Meth Enzymol 1984; 105: 121-126.
18. Paglia DE, Valentine WN. Studies on the quantitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967; 70: 158-168.
19. McCord, JM, Fridovich I. Superoxide dismutase an enzymic function for erythrocuprein Hemocuprein. J Biol Chem 244: 6049-6055.
20. Lowry OH, Rosebrough NJ, Farr AL. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-275.
21. Philpot J. Assay for MDA levels. Rad Res 1963; 3: 55-80.
22. Valko M, Leibfritz D et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39: 44-84.
23. Hee Sun Park, Sori Kim et al. The impact of oxidative stress on lung diseases. Respirology 2009; 14: 27-38.
24. Sies H. (ed.) Antioxidants in Disease, Mechanisms and Therapy, Academic Press, New York, 1996.
25. Sobradillo V, Miravitlles M, Jimenez CA, Gabriel R, Viejo JL, Masa JF, Fernandez Fau I, Villasante C. (Epidemiological study of COPD in Spain: prevalence of chronic respiratory symptoms and airflow limitation). Arch Bronconeumol 1999; 35 (4): 159-166.
26. Mannino DM, Gagnon RC, Petty TL, et al. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2000; 160: 1683-1689.
27. Vegi G, Scognamiglio A, Baldacci S, Pistelli F, Carrozzi L. Epediomology of COPD. Respiration 2001; 68: 4-19.
28. Kim DS, Kim YS, Jung KS, Chang JH, Lim CM, Lee JH et al. Prevalence of COPD in Korea: a population based spirometry survey. Am J Respir Crit Care Med 2005; 172: 842-847.
29. Kojima S, Sakakibara H, Motani S, Hirose K, Mizuno F, Ito M, et al. Effects of smoking and age on chronic obstructive pulmonary disease in Japan. J Epidemiol 2005; 15: 113-117.
30. Reddy KS, Gupta PC. Report on tobacco control in India. New Delhi: Ministry of Health and Family Welfare, Government of India; 2004 p.99-102.
31. Loganathan RS, Stover DE, Shi W, Venkatraman E. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest 2006; 129 (5): 1305-1312.
32. Kauffmann F, Becklalke MR. Sex and gender. Respiratory epidemiology in Europe. Eur Respir Mon 2000; 5: 288-304.
33. Blanc PD. The role of household exposures in lung disease among women. Eur Respir Mon 2003; 8: 118-130.
34. Wai Y, Tarlo SM. Occupational lung disease in women. Respiratory diseases in women. Eur Respir Mon 2003; 8: 131-145.
35. Di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis factor α levels and weight loss in COPD. Am J Respir Crit Care Med 1994; 150: 1453-1455.
36. Schols AM, Buurman WA, Staal van den Brekel AJ. Dentener MA. Wouters EF. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with CODP. Thorax 1996; 51: 819-824.
37. Schols AM, Creutzberg EC, Buurman WA, Campfield LA, Saris WH, Wouters EF. Plasma leptin is related to proinflammatory status and dietary intake in patients with COPD. Am J Respir Crit Care Med 1999; 160: 1220-1226.
38. De Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM. Elevated TNF Alpha production by peripheral blood monocytes of weight losing COPD patients. Am J Respir Crit Care Med 1996; 153: 633-637.
39. Gosker HR, Wouters EF, van der Vusse GJ, Schols AM. Skeletal muscle dysfunction in COPD and chronic heart failure: underlying mechanisms and therapy perspectives. (Review). American J Clin Nutr 2000; 71(5): 1033-1047.
40. Arnaud Chiolero, David Faeh, Fred Paccaud, and Jacques Cornuz. Consequences of smoking for body weight, body fat distribution, and insulin resistance. Am J Clin Nutr 2008; 87: 801-809.
41. Church T, Pryor WA. Free-radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect 1985; 64: 111-126.
42. Sethi JM, Rochester CL. Smoking and chronic obstructive pulmonary disease. Clin Chest Med 2000; 21: 67-86.
43. Jindal SK, Aggarwal AN, Chaudhry K, Chhabra SK, D'Souza GA, Gupta D, Katiyar SK, Kumar R, Shah B, Vijayan VK. A multicentric study on epidemiology of chronic obstructive pulmonary disease and its relationship with tobacco smoking and environmental tobacco smoke exposure. Indian J Chest Dis Allied Sci 2006; 48: 23-29.
44. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Anto JM. Regular physical activity modifies smoking-related lung function decline and reduces risk of COPD: a population based cohort study. Am J Respir Crit Care Med 2007; 175(5): 458-463.
45. McKinlay JB, Marceau LD. Public health matters. To boldly go. Am J Public Health 2000; 90: 25-33.
46. National Centre for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey (NHANES-III), 1988-1994: Vital Health Statistics I 1994; 32: 1-407.
47. Pierachilli J, Alessandra S, Carlucci P, Fumagalli F, Gennaro AD, Mondoni M et al. Lipid peroxidation and 5 lipo oxygenase activity in COPD. Am J Respir Crit Care Med 2005; 171: 838-843.
48. Daphne CR, Jame RJ, Haylene Nell, Mae MS, Elvism I. Diagnostic value of post bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma. International Journal of COPD 2008; 3(4): 693-699.
49. Daga MK, Chhabra R, Sharma B, Mishra. T.K. Effects of exogenous vitamin E supplementation on the lev-els of oxidants and antioxidants in chronic obstructive pulmonary disease. J Biosci 2003; 28: 7-11.
50. Cahkoglu M, Unlu A, Tamer L. The levels of serum vitamin C, malondialdehyde and erythrocyte reduced glutathione in COPD. Clin Chem Lab 2002; 40(10): 1028-1031.
51. Birgul I, Ali C, Isik R. Oxidative stress in smokers and non-smokers. Inhalation Toxicol 2007; 19 (9): 767-769.
52. AZ Reznick, Cross CE, Hu ML, Suzuki YJ, Khwaja S, Safadi A, Motchnik PA, Packer L, Halliwell B. Modification of plasma proteins by cigarette smoke as measured by protein carbonyls formation. Biochem J 1982; 286: 607-611.
53. Salon DC, Lin SW, Pacifici RE, Davies KJ. Superoxide dismutase is preferentially degraded by a proteolytic system from RBC following oxidative modification by hydrogen peroxide. Free Radic Biol Med 1998; 5: 335-339.
54. Sinet PM, Garber P. Inactivation of the human copper zinc SOD during exposure to superoxide anion and hydrogen peroxide. Arch Biochem Biophys 1981; 212: 411-416.
55. Altuntas E, Turgut T, Ilhan N, Deveci F, Mua HM, Celik I. The levels of oxidant and antioxidants in patients with COPD. Tuberk Toraks 2003; 51 (4): 373-379.
56. Arpana V, Ehtesham A, Deepak D, Singh B, Pasha M.A. Qadar. Correlation of oxidative status with BMI and lung function in COPD. Clinical Biochemistry 2007; 40: 958-963.
57. ZA Solak, Kabaroglu C, Cok G, Parildar Z et al. Effects of different levels of cigarette smoking on lipid peroxidation, Glutathione enzymes and paraoxanase activity in healthy people. Clin Exp Med 2005; 5: 99-105.
58. Liu Ling Yun, Zeng Mian, Xe Canmao et al. Oxidative stress status in patients with COPD and its relation to glucocorticoid receptor levels. J South Med Univ 2008; 28(6).
59. Nadeem A, Guru Raj H, Chhabra SK. Increased oxidative stress and altered levels of antioxidants in COPD. Inflammation FEB 2005; Vol. 29(1).